Disease · MONDO_0005057

large cell neuroendocrine carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. large cell neuroendocrine carcinoma. Diseases, record MONDO_0005057. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005057

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: large cell neuroendocrine carcinoma; Open Targets
Open Targets ID: MONDO_0005057; Open Targets
Other names: LCNEC, large cell NEC; Open Targets
Disease Ontology: DOID:0050872; Disease Ontology
NCI Thesaurus: C6875; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 5 of its 9 drugs, from ClinicalTrials.gov; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ROVALPITUZUMAB TESIRINE	CHEMBL3990011	Antibody drug conjugate	Phase 1/2	ClinicalTrials.gov	3	3	3	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 1	ClinicalTrials.gov	2	2	2	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets21

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	2	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
CD274	Programmed cell death 1 ligand 1	1	Programmed cell death 1 ligand 1 inhibitor	Phase 1	https://conductscience.org/library/genes/29126	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	1	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
DLL3	Delta-like protein 3	1	Delta-like protein 3 binding agent	Phase 1/2	https://conductscience.org/library/genes/10683	Drugs and targets
TOP2A	DNA topoisomerase II	1	DNA topoisomerase II inhibitor	Phase 2	https://conductscience.org/library/genes/7153	Drugs and targets
TOP2B	DNA topoisomerase II	1	DNA topoisomerase II inhibitor	Phase 2	https://conductscience.org/library/genes/7155	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets

1 to 10 of 21

See all 21 targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02709889	Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors	Phase 1/2	200	2020-10-19	Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma, Neuroendocrine Prostate Cancer, High Grade Gastroenteropancreatic Neuroendocrine Carcinoma, Other Neuroendocrine Carcinoma, Other Solid Tumors	ROVALPITUZUMAB TESIRINE	Its record names the disease	ClinicalTrials.gov
NCT01901653	Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer	Phase 1/2	82	2018-07-11	Recurrent Small Cell Lung Cancer	ROVALPITUZUMAB TESIRINE	Its record names the disease	ClinicalTrials.gov
NCT03591731	Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)	Phase 2	185		Neuroendocrine Carcinoma	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT02943798	Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma	Phase 2	118		Pulmonary Large Cell Neuroendocrine Carcinoma	CARBOPLATIN, ETOPOSIDE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT06717243	Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)		111		Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood, Biomarkers, Immunotherapy	ATEZOLIZUMAB, CARBOPLATIN, CISPLATIN, ETOPOSIDE	Its record names the disease	ClinicalTrials.gov
NCT05023837	Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type		40		Uncommon Pathological Types of Lung Cancer	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02500914	SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma	Phase 1	35		Small Cell Lung Cancer	ROVALPITUZUMAB TESIRINE	Its record names the disease	ClinicalTrials.gov
NCT06049966	Atezolizumab in Large Cell Neuroendocrine Carcinoma	Phase 1	22		Large Cell Neuroendocrine Carcinoma of the Lung	ATEZOLIZUMAB, CARBOPLATIN, ETOPOSIDE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26039012	RESULT	1	PubMed
42526918	DERIVED	1	PubMed
41774886	DERIVED	1	PubMed
37189075	DERIVED	1	PubMed
32438272	DERIVED	1	PubMed
32372416	DERIVED	1	PubMed
27932068	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005057

GET https://conductscience.org/api/diseases/v1/MONDO_0005057/targets?page=2

API reference For AI assistants